ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
37 announcements with these filters
Novelix Pharmaceuticals reported a total annual revenue of ₹132.34 Crore and net profit of ₹2.56 Crore for FY26. The results received an unmodified audit opinion.
Novelix Pharmaceuticals approved audited FY2026 financial results and received ₹0.42 Crore from warrant conversions. Revenue reached ₹132.34 Crore with a net profit of ₹2.56 Crore.
Novelix Pharmaceuticals declared non-applicability of the Annual Secretarial Compliance Report for FY2026. The company remains exempt due to being below SEBI LODR regulatory thresholds.
Novelix Pharmaceuticals scheduled a board meeting on May 29, 2026, to approve audited financial results and warrant conversions. Investors should track post-meeting outcomes for strategic updates.
Novelix Pharmaceuticals Limited has announced its official website address as https://novelixpharma.com in compliance with SEBI Listing Regulations. The website contains all information required under Regulation 46 of the SEBI LODR Regulations, 2015.
Novelix Pharmaceuticals Limited submitted its initial disclosure under the SEBI Large Corporate framework for FY 2026-27. As of March 31, 2026, the company reported outstanding borrowings of ₹0.81 Crore. The company confirmed it does not meet the criteria to be identified as a Large Corporate for the current financial year.
Novelix Pharmaceuticals Ltd reported net profit of ₹1 Cr (+900.0% YoY) for Q3 FY26.